New York: A single dose of an experimental Ebola virus (EBOV) vaccine completely protects monkeys against the newly emerged West African Ebola strain when given at least seven days before exposure, and partially protects them if given three days prior, says a new study.
The experimental vaccine is currently undergoing testing in a global clinical trial in humans.
The current Ebola outbreak has killed over 11,000 people mainly in Liberia, Sierra Leone and Guinea.
The positive results of this study further reveal the mechanisms by which an effective immune response is mounted against the Ebola virus, aspects of which have been unclear.
The live-attenuated vaccine, VSV-EBOV, uses genetically engineered vesicular stomatitis virus (VSV) to carry an EBOV gene that has safely induced protective immunity in macaques, the study noted.
In the study by Andrea Marzi from US National Institutes of Health (NIH) VSV-EBOV was administered to groups of macaques 28, 21, 14, seven, or three days before infection with the current outbreak strain EBOV-Makona.
No adverse effects were detectable after immunisation with the lethal dose, and the animals were then monitored for 42 days.
The control group, which was administered a vaccine known not to be effective, showed severe symptoms of Ebola and did not survive.
One animal in the day-three VSV-EBOV vaccination group also did not survive, while the other two animals in this group presented mild and moderate symptoms of Ebola but eventually cleared the virus.
All nine remaining animals in the day 28, 21, 14, and seven vaccination groups did not develop any clinical signs of disease.
Roorkee, October 9, 2017 : Dengue and Chikungunya are known to strike fear in the country every year, so much so that the health graph of the city registers a steep rise in these cases. Both of the water-borne diseases, characterized by high fever and pain in the joints, take a toll on our lives. So far, there is no vaccine to immunize people against the spread of the Dengue and Chikungunya virus. However, researchers at IIT-Roorkee have now discovered that a commonly-utilized de-worming drug can be efficiently used for treatments against Chikungunya.
According to a report by PTI, Shailly Tomar, lead researcher and a professor at Indian Institute of Technology (IIT) Roorkee in Uttarakhand was quoted as saying, “Our research has shown that piperazine, a drug existing in the market, is successful in curbing the spread and replication of the Chikungunya virus in a lab setting.”
The drug, Piperazine, is usually used in de-worming treatments against round-words and pinworms. Using their expertise in virology and structure biology, experts have now discovered the anti-viral capabilities of the drug that can potentially prompt new therapies against the fatal, mosquito borne disease.
The researchers are currently testing the molecule on animals, and will consequently take it to clinical trials.
The molecular details uncovered in the study, which has been published in the journal Antiviral Research, will be additionally used to plan piperazine-derivative medications that are more compelling to fight against the Chikungunya virus.
Using X-ray crystallographic technique, in combination with computational science and fluorescence strategies, the researchers discovered that piperazine binds itself with the hydrophobic (water-hating) pocket of capsid protein present in the Chikungunya virus, which can reduce the spread of the virus.
“This pocket is key to the replication of the virus and its spread inside a host. Inhibiting the pocket prevents budding and spread of the virus and can help in treating the virus effectively using existing drugs,” Tomar said.
Chikungunya has become a major public health concern, with an increasing number of people being plagued by the disease every year.
At present, there are no immunizations or anti-viral medications available to cure Chikungunya, and the treatment is focused on mitigating the side effects related with the disease.
Developing a new anti-viral drug molecule can take up to 10 years. To tend to the disease on an immediate basis, Professor Tomar added, “We are looking at repositioning existing, approved drugs and testing these to see if they might inhibit or kill pathogenic viruses.”
Carbohydrates on the surface of malaria parasites play an important role in their ability to infect mosquito Andy human hosts
The new research is aimed at improving malaria vaccine design
It’s hoped that a version of RTS, S with added carbohydrates will perform better than the current vaccine
New Delhi, September 18, 2017: Offering vital clues to improving malaria vaccine, an international research team has shown that carbohydrates on the surface of malaria parasites play a critical role in their ability to infect mosquito and human hosts.
The discovery, published in the journal Nature Communications, also suggests steps that may improve the only malaria vaccine approved to protect people against Plasmodium falciparum malaria — the most deadly form of the disease.
The team had shown that the malaria parasite “tags” its proteins with carbohydrates in order to stabilise and transport them and that this process was crucial to completing the parasite’s life cycle.
“Interfering with the parasite’s ability to attach these carbohydrates to its proteins hinders liver infection and transmission to the mosquito and weakens the parasite to the point that it cannot survive in the host,” said Justin Boddey from Walter and Eliza Hall Institute in Parkville, Victoria, Australia.
Malaria infects over 200 million people worldwide each year and kills around 650,000 people, predominantly pregnant women and children. Efforts to eradicate malaria require the development of new therapeutics, particularly an effective malaria vaccine.
The first malaria vaccine approved for human use — RTS,S/AS01 — got the nod of the European regulators in July 2015 but has not been as successful as hoped with marginal efficacy that wanes over time.
The new research is aimed at improving malaria vaccine design.
“The protein used in the RTS, S vaccine mimics one of the proteins we’ve been studying on the surface of the malaria parasite that is readily recognised by the immune system,” Ethan Goddard-Borger from Walter and Eliza Hall Institute said.
“With this study, we’ve shown that the parasite protein is tagged with carbohydrates, making it slightly different to the vaccine, so the antibodies produced may not be optimal for recognising target parasites.”
“It may be that a version of RTS, S with added carbohydrates will perform better than the current vaccine,” he said, adding that there were many documented cases where attaching carbohydrates to a protein improved its efficacy as a vaccine. (IANS)
Approximately 11,000 people died in the Ebola outbreak that hit West Africa from 2014 to 2016
Many battled vision problems and headaches that lasted for months
They show some quite distinct scarring patterns
Sierra Leone, West Africa, August 25, 2017: Patients who survive infection with the Ebola virus often continue to face numerous health problems. New research finds 80 percent of Ebola survivors suffer disabilities one year after being discharged from the hospital.
Approximately 11,000 people died in the Ebola outbreak that hit West Africa from 2014 to 2016; tens of thousands more who were infected survived.
Of those survivors, many battled vision problems and headaches that lasted for months.
Researchers at the University of Liverpool, the UK and the Liverpool School of Tropical Medicine, UK are studying what’s called post-Ebola syndrome. One of the senior authors of the study, Dr. Janet Scott, says researchers are unsure why survivors experience such disabilities.
“I’m not sure we’ve quite gotten to the bottom of it yet,” Scott said. “The idea that you go through something as horrific as Ebola and just walk away from that unscathed was always a bit of a vain hope. So, it could be the inflammatory response. It could be damage to the muscles, and it could be the persistence of the virus in some cases. It could be all of those things.”
Scott says problems found in Ebola survivors’ eyes may provide clues to what is happening elsewhere in the body.
“They show some quite distinct scarring patterns,” she said. “There’s definitely scar tissue there. We can see it in the eyes. We can’t see it in the rest of the body, but I’m sure it’s in the rest of the body because the patients are coming in with this huge range of problems.”
The disabilities were reported in past cases of Ebola outbreak, as well. However, because past outbreaks were smaller and there were few survivors, researchers were not able to do major, long-term studies on the after effects.
This time, said Scott, “There are 5,000 survivors or thereabouts in Sierra Leone, and more in Guinea and Liberia. So, it’s an opportunity from a research point of view to find out the full spectrum of sequelae … the things that happen after an acute illness.”
Military Hospital 34 in Freetown, Sierra Leone, also took part in the study, helping to recruit 27 Ebola survivors and 54 close contacts who were not infected. About 80 percent of survivors reported disabilities compared to 11 percent of close contacts.
“The problems we’re seeing in Ebola survivors, this is not due just to the tough life in Sierra Leone. This is more than likely down to their experience in Ebola,” Scott said.
The research was led by Dr. Soushieta Jagadesh, who said: “a year following acute disease, survivors of West Africa Ebola Virus Disease continue to have a higher chance of disability in mobility, cognition, and vision.”
“Issues such as anxiety and depression persist in survivors and must not be neglected,” she added.
Scott hopes the findings can be used to provide better care in the event of another Ebola outbreak, no matter where it is. In the West Africa outbreak, the first goal was to contain the epidemic, followed by reducing the death rate.
“If I was treating an Ebola patient again, it has to be more than just surviving,” Scott said. “You have to try to make people survive well. Surviving with half your body paralyzed or with your vision impaired and being unable to care for your family or earn a living isn’t really enough. So, what I would like to do is to focus on that aspect to make people survive better and survive well.” (VOA)